The company announced results of three clinical trials on immune health ingredients and children and infants.
Fonterra (Auckland, New Zealand) announced three new developments with its infant nutrition ingredients at the XVI Congress of Paediatricians held in Moscow last month. The multinational dairy co-op presented results of three clinical trials on various dairy-format ingredients.
In a clinical study on Fonterra’s “complex dairy lipids,” infants consuming formula with these lipids showed improvement in cognitive development, compared to infants consuming a standard infant formula. Fonterra’s complex lipids previously demonstrated activity against rotavirus diarrhea, which affects an estimated 95% of children within their first five years of life.
A second study, to be published in the journal Clinical and Experimental Allergy, featured 425 infants consuming placebo or DR20, Fonterra’s Lactobacillus rhamnosis HN001 probiotic strain. After two years of supplementation, infants in the DR20 group showed reduced prevalence of the skin allergy eczema (atopic dermatitis) by 45%, compared to placebo. After four years of follow-up, the DR20 group continued to show a lower prevalence of eczema.
Lastly, Fonterra offered up the results of a recent human clinical trial on infant formula with its DR10 probiotic strain (Bifidobacterium animalis subspecies lactis HN019) and a prebiotic galactooligosacharide (GOS). The probiotic- and GOS-enriched infant formula was linked to reduced risks of several childhood morbidities (e.g. dysentery, pneumonia, and severe-acute lower respiratory infections) compared to placebo milk in a trial of 312 children.
Brightseed launches clinically validated ingredient, Bio Gut Core, to support gut barrier function
May 21st 2025The low-dose, easy-to-formulate ingredient is a proprietary blend of two bioactives – N-trans caffeoyltyramine (NCT) and N-trans feruloyltyramine (NFT) – which were discovered by the company’s Forage AI platform.
The Nutritional Outlook Podcast Episode 39: Nutritional Outlook's Ingredients to Watch in 2025
February 25th 2025In this episode, Nutritional Outlook interviews Scott Dicker, market insights director from market researcher SPINS, about ingredients and product categories nutraceutical and nutrition product manufacturers should watch in 2025.
Nutrition during adolescence: A missed opportunity for optimal cognitive health?
May 20th 2025The Cognitive Health Committee of the Institute for the Advancement of Food and Nutrition Sciences (IAFNS) explores the significant gap in our knowledge about the impact nutrition has on adolescent cognitive development.
A country-by-country blueprint for nutraceutical success in Europe
May 20th 2025The European nutraceutical market is growing rapidly, but the continent is not a monolith when it comes to consumer trends and product innovation. This article is a blue-print for what nutraceutical success looks like in different European countries.